I have no problem with the statement about discard
Post# of 148188
The only issue I have is that they have so much trial product that they expect to discard it (how much is unknown). The investors purchased this and while CYDY is very good about being efficient and using their funds wisely, I view having so much excess trial product that they overestimated (could be due to increased dosage) or didn't realize the difference between trial and commercial product. My thought on this is just a few months ago they were saying we have '$190M or $200M worth of commercial grade product and only spent $190M, so essentially we developed the technology for free'.....then a couple months ago they began breaking out commercial grade ($50M) from trial grade ($150M). That infers to me they didn't realize the difference until recently.
This is a win in that we can get some use from a product that has little to no value otherwise. If we can recoup our cost basis, it is a win IMO and anything else is cherries and sprinkles.